CD8A and melanoma: showed that T cell immunoreceptors with Ig and ITIM domains (TIGIT)+ PD-1+ tumor antigen-specific CD8+ T cells from patients with melanoma displayed an effector memory phenotype and responded well to PD-1 targeted therapies (37).